Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Rajul Kothari, Peter A Argenta, Jeffrey Fowler, Jori Carter, William Shimp

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalArchive of Oncology
Volume18
Issue number1-2
DOIs
StatePublished - Jul 1 2010

Fingerprint

Estrogen Receptor Modulators
Ovarian Neoplasms
Platinum
Therapeutics
Drug Therapy

Keywords

  • Antineoplastic Agents
  • Aromatase
  • Hormonal
  • Ovarian Neoplasms
  • Selective Estrogen Receptor Modulators
  • Tamoxifen

Cite this

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease : A case report and review of the literature. / Kothari, Rajul; Argenta, Peter A; Fowler, Jeffrey; Carter, Jori; Shimp, William.

In: Archive of Oncology, Vol. 18, No. 1-2, 01.07.2010, p. 32-35.

Research output: Contribution to journalArticle

@article{8bd067f2920a495889f0dd38206e9e6a,
title = "Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature",
abstract = "Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.",
keywords = "Antineoplastic Agents, Aromatase, Hormonal, Ovarian Neoplasms, Selective Estrogen Receptor Modulators, Tamoxifen",
author = "Rajul Kothari and Argenta, {Peter A} and Jeffrey Fowler and Jori Carter and William Shimp",
year = "2010",
month = "7",
day = "1",
doi = "10.2298/AOO1002032K",
language = "English (US)",
volume = "18",
pages = "32--35",
journal = "Archive of Oncology",
issn = "0354-7310",
publisher = "Institute of Oncology Sremska Kamenica",
number = "1-2",

}

TY - JOUR

T1 - Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease

T2 - A case report and review of the literature

AU - Kothari, Rajul

AU - Argenta, Peter A

AU - Fowler, Jeffrey

AU - Carter, Jori

AU - Shimp, William

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

AB - Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

KW - Antineoplastic Agents

KW - Aromatase

KW - Hormonal

KW - Ovarian Neoplasms

KW - Selective Estrogen Receptor Modulators

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=78649496224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649496224&partnerID=8YFLogxK

U2 - 10.2298/AOO1002032K

DO - 10.2298/AOO1002032K

M3 - Article

AN - SCOPUS:78649496224

VL - 18

SP - 32

EP - 35

JO - Archive of Oncology

JF - Archive of Oncology

SN - 0354-7310

IS - 1-2

ER -